ClinicalTrials.gg
RecruitingNCT07362992Updated Jul 2, 2026

Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery

An Early Phase 1 interventional study of Tranexamic Acid (Topical) and Normal Saline (Placebo) in Cesarean Delivery, Postpartum Hemorrhage (PPH) and Intraoperative Blood Loss, sponsored by Wolfson Medical Center. Recruiting at 4 sites in Israel. Open to female participants aged 18 Years to 51 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Wolfson Medical Center · Early Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 51 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies testing Tranexamic Acid in Postpartum Hemorrhage — 8 open to participants now, 8 under way, 3 of them phase 3. Tranexamic Acid · Postpartum Hemorrhage.

Planned enrollment
33rd of 50
112 · median 198
Started
2026
the only one that year
Phase 1
2 of 50
2 open now
Registered
49th of 50
by date

Among the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, this one is the 33rd largest by planned enrollment, is the only one that started in 2026, is one of 2 in phase 1, and was the 49th registered.

Postpartum Hemorrhage

471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

Browse Postpartum Hemorrhage studies →

Open to participants now

8 of the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage are open now, in 8 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 51 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether applying topical tranexamic acid (TXA) directly to the uterine incision during cesarean delivery can reduce surgical bleeding compared to placebo. The study will include pregnant women aged 18-51 undergoing elective cesarean delivery at term (37 weeks or more).

The main questions it aims to answer are:

  • Does topical TXA shorten uterine closure time?
  • Does topical TXA reduce the need for additional hemostatic sutures? Researchers will compare women receiving topical TXA to those receiving placebo (normal saline) to see if TXA reduces intraoperative bleeding and improves surgical outcomes.

Participants will:

  • Be randomly assigned to receive either topical TXA or placebo during cesarean delivery.
  • Have standard surgery and postoperative care identical in both groups.
  • Provide routine clinical data, including hemoglobin levels and recovery outcomes, from their medical records.
Read the detailed description

Cesarean delivery carries a recognized risk of significant intraoperative bleeding despite standard uterotonic use and established surgical techniques. Tranexamic acid (TXA), an antifibrinolytic medication, reduces surgical blood loss when administered intravenously, but little is known about the effectiveness of topical TXA applied directly to the uterine incision during cesarean delivery. Evidence from other surgical fields suggests that topical TXA may reduce bleeding with minimal systemic absorption.

This study is a multi-center, randomized, placebo-controlled trial designed to evaluate whether topical TXA decreases intraoperative bleeding during elective cesarean delivery at term. A total of 112 participants will be randomized in a 1:1 ratio to receive either TXA (500 mg diluted in 15 mL saline) or an identical-appearing saline placebo. The study drug is applied by spraying the solution directly onto the uterine incision after placental delivery and before each layer of uterine closure. Randomization will be stratified by site, and allocation will be concealed using sequentially numbered envelopes opened by a scrub nurse.

All cesarean procedures will follow a standardized operative technique to minimize variability. Intraoperative and postoperative data will be collected from medical records, including operative characteristics, perioperative hemoglobin values, use of additional hemostatic measures, length of stay, and maternal or neonatal complications. Safety monitoring will focus on thromboembolic events, allergic reactions, and postoperative infections, with periodic review by an independent safety officer.

This trial aims to determine whether a localized, low-cost antifibrinolytic intervention can improve hemostasis during cesarean delivery and potentially be incorporated into routine surgical practice.

03

Conditions studied

  • Cesarean Delivery
  • Postpartum Hemorrhage (PPH)
  • Intraoperative Blood Loss
  • Hemostasis

Keywords

  • Tranexamic Acid
  • Topical Tranexamic Acid
  • Hexakapron
  • Cesarean Delivery
  • Cesarean Section
  • Elective Cesarean
  • Postpartum Hemorrhage
  • Intraoperative Bleeding
  • Blood Loss Prevention
  • Uterine Closure
  • Randomized Controlled Trial
  • Maternal Outcomes
04

Who can participate

Ages eligible
18 Years to 51 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 to 51 years
  • Singleton pregnancy
  • Elective cesarean delivery scheduled at ≥37+0 weeks of gestation
  • First or second cesarean delivery only
  • Low transverse uterine incision planned
  • Double-layer uterine closure using 1-0 Vicryl sutures
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • Known allergy or to tranexamic acid (TXA)
  • History of bleeding or coagulation disorders
  • Previous postpartum hemorrhage
  • Placenta previa or placenta accreta spectrum
  • Presence of uterine myomas
  • Current use of anticoagulant or antiplatelet medications
  • Planned or intraoperative conversion to general anesthesia
  • Known uterine malformations
  • Known bleeding tendency or thromboembolic disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    Topical Tranexamic Acid (TXA) Group

    Participants in this group will receive topical tranexamic acid (TXA) applied directly to the uterine incision during cesarean delivery. After the baby and placenta are delivered, the surgeon will spray a solution containing 500 mg of TXA (one ampule, 5 mL) diluted in 15 mL of normal saline onto the uterine incision before suturing begins. After the first layer of sutures is placed, a second syringe of the same TXA solution will be sprayed before the second layer of closure. All other aspects of the surgical technique and postoperative care will follow standard practice.

    Drug: Tranexamic Acid (Topical)

  • Placebo comparator
    Placebo (Normal Saline) Group

    Participants in this group will receive a placebo solution of normal saline applied in the same manner and at the same time points as in the TXA group. After the baby and placenta are delivered, the surgeon will spray 20 mL of sterile saline onto the uterine incision before closure, and again before completing the second layer of sutures. All other surgical and postoperative procedures will be identical to those in the TXA group.

    Other: Normal Saline (Placebo)

Interventions

  • DrugTranexamic AcidStudies of Tranexamic AcidTranexamic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This intervention involves topical application of tranexamic acid (TXA) directly to the uterine incision during cesarean delivery, rather than the conventional intravenous route. A solution containing 500 mg of TXA (one ampule, 5 mL) diluted in 15 mL of normal saline is sprayed evenly over the uterine incision surface after placental delivery and before suturing. A second application of the same solution is sprayed before the second layer of uterine closure. This localized, site-directed use is designed to reduce intraoperative bleeding with minimal systemic absorption, distinguishing it from previously studied intravenous TXA regimens.

    Also known as: Hexakapron

  • OtherNormal Saline (Placebo)

    This comparator intervention involves topical application of sterile normal saline to the uterine incision at the same time points as in the TXA arm - after placental delivery and before each layer of uterine closure. This placebo control enables a direct comparison to determine whether the topical TXA application provides added benefit in reducing intraoperative bleeding.

    Also known as: NaCl 0.9%

06

What researchers measure

Primary outcomes

  1. Uterine closure time (minutes)

    Time from placement of the first uterine stitch to completion of the final uterine stitch including any additional hemostatic sutures (In minutes)

    Time frame: Intraoperative (during the index cesarean delivery)

  2. Number of additional hemostatic sutures (count)

    Total number of extra hemostatic stitches needed for bleeding control beyond the routine two-layer uterine closure

    Time frame: Intraoperative (during the index cesarean delivery)

Secondary outcomes

  1. Estimated intraoperative blood loss (mL)

    Blood loss estimated by the operating surgeon during the cesarean delivery, recorded at the end of the procedure using standardized estimation protocols.

    Time frame: Intraoperative (during the index cesarean delivery)

  2. Change in hemoglobin levels

    Difference between preoperative hemoglobin concentration and hemoglobin measured 16-24 hours after surgery, expressed in g/dL.

    Time frame: 16-24 hours postoperatively

  3. Need for additional uterotonic agents

    Administration of additional uterotonic medications beyond routine prophylactic Oxycontin during surgery and up to 24 postoperative

    Time frame: Intra-operative to 24 hours postoperative

  4. Need for blood transfusion

    Incidence of red blood cell transfusion due to surgical blood loss or postoperative anemia.

    Time frame: within 30 days postoperativly

  5. Duration of hospital admission (days)

    Number of days from the cesarean delivery to hospital discharge.

    Time frame: Postoperative within 30 days from delivery

  6. Postoperative complications

    Occurrence of any postoperative maternal complications, including fever, endometritis, wound infection, thromboembolic events, or reoperation

    Time frame: Up to 30 days after surgery

  7. Post-discharge emergency department visits or hospital readmissions

    Any maternal emergency department visits or readmissions related to the delivery within one month of cesarean section.

    Time frame: Within 30 days postpartum

07

Study locations

1 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2025
First posted
Jan 23, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 31, 2028
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07362992
Collaborators
Rabin Medical Center, Meir Medical Center, Kaplan Medical Center
Responsible party
Liat Mor (principal investigator, Wolfson Medical Center) — Principal investigator
First posted
Jan 23, 2026
Start date
Jul 1, 2026
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 2, 2026

Study contacts

Liat Mor
Contact
liatmor1@gmail.com
+972546738294
Amichai Rottenstreich
principal investigator · Edith Wolfson Medical center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion